The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.

Flasche, S; Jit, M; Rodríguez-Barraquer, I; Coudeville, L; Recker, M; Koelle, K; Milne, G; Hladish, TJ; Perkins, TA; Cummings, DA; +11 more... Dorigatti, I; Laydon, DJ; España, G; Kelso, J; Longini, I; Lourenco, J; Pearson, CA; Reiner, RC; Mier-Y-Terán-Romero, L; Vannice, K; Ferguson, N; (2016) The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study. PLoS medicine, 13 (11). e1002181. ISSN 1549-1277 DOI: https://doi.org/10.1371/journal.pmed.1002181

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1371/journal.pmed.1002181

Abstract

Share

Download

Filename: The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia)A Model Comparison Study.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar